Publication Name	World Journal of Pharmacology
Manuscript ID	115880
Country	Bangladesh

Category	Pharmacology & Pharmacy
Manuscript Type	Meta-Analysis
Article Title	Re-evaluating aspirin in the era of potent P2Y12 inhibitors: Ticagrelor monotherapy after percutaneous coronary intervention
Manuscript Source	Unsolicited Manuscript
All Author List	Abdul Basit, Muhammad Hamza Aslam, Muhammad Moneeb Anwar, Muhammad Ahmad Sarwar, Ammara Akram, Qamar Ismail, Abdullah Iftikhar and Majeed Haq
Funding Agency and Grant Number
Corresponding Author	Majeed Haq, Department of Pharmacology, Shaheed Suhrawardy Medical College and Hospital, Sher-E-Bangla Nagar, Dhaka 1207, Bangladesh. b0807621@gmail.com
Key Words	Ticagrelor; Dual antiplatelet therapy; Percutaneous coronary intervention; P2Y12 inhibitors; Aspirin
Core Tip	Ticagrelor monotherapy after short-term dual antiplatelet therapy significantly reduces bleeding without increasing ischemic risk in high-risk percutaneous coronary intervention patients. This meta-analysis of > 20000 patients supports aspirin discontinuation after 1-3 months of dual antiplatelet therapy. Findings reinforce evolving guidelines toward simplified, safer antiplatelet strategies post-percutaneous coronary intervention.
Citation	Basit A, Aslam MH, Anwar MM, Sarwar MA, Akram A, Ismail Q, Iftikhar A, Haq M. Re-evaluating aspirin in the era of potent P2Y12 inhibitors: Ticagrelor monotherapy after percutaneous coronary intervention. World J Pharmacol 2026; In press

Received	2025-10-29 14:00
Peer-Review Started	2025-10-29 14:00
First Decision by Editorial Office Director	2026-01-19 08:21
Return for Revision	2026-01-19 08:21
Revised	2026-02-02 15:07
Publication Fee Transferred
Second Decision by Editor	2026-02-25 02:34
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-02-25 10:06
Articles in Press	2026-02-25 10:06
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2220-3192 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com